---
title: "諾和諾德 ADR 恢復交易，瞬間跳水，跌幅擴大至 8.4%"
description: "諾和諾德 ADR 恢復交易，瞬間跳水，跌幅擴大至 8.4%。風險提示及免責條款 市場有風險，投資需謹慎。本文不構成個人投資建議，也未考慮到個別用户特殊的投資目標、財務狀況或需要。用户應考慮本文中的任何意見、觀點或結論是否符合其特定狀況。據此投資，責任自負。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274689185.md"
published_at: "2026-02-03T16:57:59.000Z"
---

# 諾和諾德 ADR 恢復交易，瞬間跳水，跌幅擴大至 8.4%

> 諾和諾德 ADR 恢復交易，瞬間跳水，跌幅擴大至 8.4%。風險提示及免責條款 市場有風險，投資需謹慎。本文不構成個人投資建議，也未考慮到個別用户特殊的投資目標、財務狀況或需要。用户應考慮本文中的任何意見、觀點或結論是否符合其特定狀況。據此投資，責任自負。

諾和諾德 ADR 恢復交易，瞬間跳水，跌幅擴大至 8.4%。

風險提示及免責條款

市場有風險，投資需謹慎。本文不構成個人投資建議，也未考慮到個別用户特殊的投資目標、財務狀況或需要。用户應考慮本文中的任何意見、觀點或結論是否符合其特定狀況。據此投資，責任自負。

### Related Stocks

- [NVO.US - 諾和諾德公司](https://longbridge.com/zh-HK/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Assessing Novo Nordisk (NYSE:NVO) Valuation After Share Price Pullback And GLP 1 Growth Prospects | Novo Nordisk (NYSE:NVO) has experienced a 24% decline in share price over the past month, with a total return of 45% dow | [Link](https://longbridge.com/zh-HK/news/276640505.md) |
| Novo Nordisk Proposes Two Additional New Board Appointments | Danish pharmaceutical company Novo Nordisk is proposing three new appointments to its board of directors for the annual  | [Link](https://longbridge.com/zh-HK/news/276442777.md) |
| TLV Says No to Including Wegovy in High-Cost Protection Scheme | The Dental and Pharmaceutical Benefits Agency (TLV) has denied Novo Nordisk's request to include the weight loss drug We | [Link](https://longbridge.com/zh-HK/news/276605024.md) |
| Key facts: Novo Nordisk Faces Challenges with CagriSema; $35B M&A Plans | J.P. Morgan analysts raised concerns about CagriSema's underperformance, which may affect demand and long-term sales for | [Link](https://longbridge.com/zh-HK/news/276670594.md) |
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/zh-HK/news/276447697.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。